RARE Ultragenyx Pharmaceutical Inc.

62.04
+1  (2%)
Previous Close 60.89
Open 60.98
Price To book 5.30
Market Cap 2.59B
Shares 41,726,000
Volume 887,963
Short Ratio 10.96
Av. Daily Volume 587,045

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. BLA filing due 1H 2017.
rhGUS
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 to be initiated 1H 2017.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data due 2H 2017.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3 data released April 18, 2017 - primary endpoint met, two of three secondary endpoints met (missed on pain).
KRN23
X-Linked Hypophosphatemia (XLH) - adult
Interim data released April 2016. Additional data released September 2016.
KRN23
Tumor-induced osteomalacia (TIO)
Phase 3 enrollment commenced October 2016.
KRN23
X-Linked Hypophosphatemia (XLH) - pediatric
Phase 2 initiated March 2014. Data released March 22, 2017 - primary endpoint not met.
UX007 (triheptanoin)
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase 2 interim data released October 2015. 78-week data released November 30, 2016. Phase 3 planned for 2017.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Latest News

  1. Company News for April 20, 2017
  2. Energy, biotech, financials & more in the trader blitz
  3. Analyst Sees Ultragenyx Shares Range Bound Despite Positive Data
  4. Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
  5. Why Ultragenyx Pharmaceutical Stock Is Spiking Today
  6. The Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data
  7. Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data
  8. Ultragenyx surges on positive results for hypophosphatemia drug test
  9. After-hours buzz: IBM, LRCX, RARE & more
  10. Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-linked Hypophosphatemia
  11. Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
  12. Ultragenyx's (RARE) XLH Drug Positive in Phase II Study
  13. Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors
  14. Ultragenyx and Kyowa Kirin International Announce Positive Data from Paediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia
  15. Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia
  16. Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : March 24, 2017
  17. Is It Time To Buy Ultragenxy?
  18. Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study
  19. Biotech Premarket Movers: Insys, Ultragenyx, Alexion
  20. Ultragenyxs’ Seizure Drug Fails Study